EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia

被引:73
作者
Balgobind, B. V. [1 ]
Lugthart, S. [3 ]
Hollink, I. H. [1 ]
Arentsen-Peters, S. T. J. C. M. [1 ]
van Wering, E. R. [2 ]
de Graaf, S. S. N. [2 ,4 ]
Reinhardt, D. [5 ]
Creutzig, U. [6 ]
Kaspers, G. J. L. [7 ]
de Bont, E. S. J. M. [8 ]
Stary, J. [9 ]
Trka, J. [9 ]
Zimmermann, M. [5 ]
Beverloo, H. B. [10 ]
Pieters, R. [1 ]
Delwel, R. [3 ]
Zwaan, C. M. [1 ]
van den Heuvel-Eibrink, M. M. [1 ]
机构
[1] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands
[2] DCOG, The Hague, Netherlands
[3] Erasmus MC, Dept Hematol, Rotterdam, Netherlands
[4] Radboud Univ Nijmegen Med Ctr, Dept Pediat Oncol Hematol, Nijmegen, Netherlands
[5] Hannover Med Sch, Dept Pediat Hematol Oncol, AML BFM Study Grp, D-3000 Hannover, Germany
[6] Univ Hosp, Dept Pediat Hematol Oncol, AML BFM Study Grp, Munster, Germany
[7] Vrije Univ Amsterdam Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands
[8] Univ Groningen, Beatrix Childrens Hosp, Univ Med Ctr Groningen, Dept Pediat Oncol Hematol, Groningen, Netherlands
[9] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol Oncol, Prague, Czech Republic
[10] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands
关键词
EVI1; expression; pediatric AML; MDS1/EVI1; ZINC-FINGER PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW-CELLS; GENE-EXPRESSION; ONCOLOGY-GROUP; TREATMENT STRATEGY; TRANSFORMING GENE; PR DOMAIN; AML; ACTIVATION;
D O I
10.1038/leu.2010.47
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Overexpression of the ecotropic virus integration-1 (EVI1) gene (EVI1+), localized at chromosome 3q26, is associated with adverse outcome in adult acute myeloid leukemia (AML). In pediatric AML, 3q26 abnormalities are rare, and the role of EVI1 is unknown. We studied 228 pediatric AML samples for EVI1+ using gene expression profiling and RQ-PCR. EVI1+ was found in 20/213 (9%) of children with de novo AML, and in 4/8 with secondary AML. It was predominantly found in MLL-rearranged AML (13/47), monosomy 7 (2/3), or FAB M6/7 (6/10), and mutually exclusive with core-binding factor AML, t(15;17), and NPM1 mutations. Fluorescent in situ hybridization (FISH) was performed to detect cryptic 3q26 abnormalities. However, none of the EVI1+ patients harbored structural 3q26 alterations. Although significant differences in 4 years pEFS for EVI1+ and EVI1 pediatric AML were observed (28%+/- 11 vs 44%+/- 4, P=0.04), multivariate analysis did not identify EVI1+ as an independent prognostic factor. We conclude that EVI1+ can be found in similar to 10% of pediatric AML. Although EVI1+ was not an independent prognostic factor, it was predominantly found in subtypes of pediatric AML that are related with an intermediate to unfavorable prognosis. Further research should explain the role of EVI1+ in disease biology in these cases. Remarkably, no 3q26 abnormalities were identified in EVI1+ pediatric AML. Leukemia (2010) 24, 942-949; doi:10.1038/leu.2010.47; published online 1 April 2010
引用
收藏
页码:942 / 949
页数:8
相关论文
共 50 条
[1]
[Anonymous], 2007, R LANGUAGE ENV STAT
[2]
Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5′-ends [J].
Aytekin, M ;
Vinatzer, U ;
Musteanu, M ;
Raynaud, S ;
Wieser, R .
GENE, 2005, 356 :160-168
[3]
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis [J].
Balgobind, Brian V. ;
Van Vlierberghe, Pieter ;
van den Ouweland, Ans M. W. ;
Beverloo, H. Berna ;
Terlouw-Kromosoeto, Joan N. R. ;
van Wering, Elisabeth R. ;
Reinhardt, Dirk ;
Horstmann, Martin ;
Kaspers, Gertjan J. L. ;
Pieters, Rob ;
Zwaan, C. Michel ;
Van den Heuvel-Eibrink, Marry M. ;
Meijerink, Jules P. P. .
BLOOD, 2008, 111 (08) :4322-4328
[4]
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study [J].
Balgobind, Brian V. ;
Raimondi, Susana C. ;
Harbott, Jochen ;
Zimmermann, Martin ;
Alonzo, Todd A. ;
Auvrignon, Anne ;
Beverloo, H. Berna ;
Chang, Myron ;
Creutzig, Ursula ;
Dworzak, Michael N. ;
Forestier, Erik ;
Gibson, Brenda ;
Hasle, Henrik ;
Harrison, Christine J. ;
Heerema, Nyla A. ;
Kaspers, Gertjan J. L. ;
Leszl, Anna ;
Litvinko, Nathalia ;
Lo Nigro, Luca ;
Morimoto, Akira ;
Perot, Christine ;
Pieters, Rob ;
Reinhardt, Dirk ;
Rubnitz, Jeffrey E. ;
Smith, Franklin O. ;
Stary, Jan ;
Stasevich, Irina ;
Strehl, Sabine ;
Taga, Takashi ;
Tomizawa, Daisuke ;
Webb, David ;
Zemanova, Zuzana ;
Zwaan, C. Michel ;
van den Heuvel-Eibrink, Marry M. .
BLOOD, 2009, 114 (12) :2489-2496
[5]
BALGOBIND BV, 2008, ASH ANN M, V112, P1512
[6]
Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the children's oncology group [J].
Barnard, Dorothy R. ;
Alonzo, Todd A. ;
Gerbing, Robert B. ;
Lange, Beverly ;
Woods, William G. .
PEDIATRIC BLOOD & CANCER, 2007, 49 (01) :17-22
[7]
CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[8]
EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression [J].
Cattaneo, Francesca ;
Nucifora, Giuseppina .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2008, 105 (02) :344-352
[9]
Malignant transformation initiated by MII-AF9: Gene dosage and critical target cells [J].
Chen, Weili ;
Kumar, Ashish R. ;
Hudson, Wendy A. ;
Li, Quanzhi ;
Wu, Baolin ;
Staggs, Rodney A. ;
Lund, Erik A. ;
Sam, Thien N. ;
Kersey, John H. .
CANCER CELL, 2008, 13 (05) :432-440
[10]
Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials [J].
Creutzig, U ;
Zimmermann, M ;
Ritter, J ;
Reinhardt, D ;
Hermann, J ;
Henze, G ;
Jürgens, H ;
Kabisch, H ;
Reiter, A ;
Riehm, H ;
Gadner, H ;
Schellong, G .
LEUKEMIA, 2005, 19 (12) :2030-2042